Liveyon – FDA 483, Sep 21, 2018
An FDA inspection of Liveyon, an own label stem cell distributor in Yorba Linda, CA, revealed serious deficiencies across its operations. The firm failed to report multiple fatal or life-threatening adverse reactions involving communicable diseases related to HCT/Ps. Significant issues were also noted in complaint handling, communicable disease testing interpretation, product release criteria, equipment calibration, HCT/P storage, and shipping conditions.
ID · 98e56818-e186-46c3-935f-6ef233e45d0b
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.